Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ASTRAZENECA LIMITED,Durvalumab,"biliary tract cancer, Locally advanced or metastatic, in combination with chemotherapy",Durvalumab (Imfinzi),Options for investment,Hospital,Oncology Agents and Immunosuppressants
